Pliant Therapeutics Inc (PLRX) - Total Assets
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) holds total assets worth $276.60 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Pliant Therapeutics Inc's book value for net asset value and shareholders' equity analysis.
Pliant Therapeutics Inc - Total Assets Trend (2017–2024)
This chart illustrates how Pliant Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Pliant Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Pliant Therapeutics Inc's total assets of $276.60 Million consist of 91.3% current assets and 8.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.9% |
| Accounts Receivable | $2.30 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Pliant Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Pliant Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pliant Therapeutics Inc's current assets represent 91.3% of total assets in 2024, an increase from 71.8% in 2017.
- Cash Position: Cash and equivalents constituted 17.9% of total assets in 2024, down from 64.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Pliant Therapeutics Inc Competitors by Total Assets
Key competitors of Pliant Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Pliant Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.93 | 10.26 | 25.07 |
| Quick Ratio | 13.93 | 10.26 | 25.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $227.96 Million | $370.08 Million | $279.15 Million |
Pliant Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Pliant Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.34 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -22.5% |
| Total Assets | $396.95 Million |
| Market Capitalization | $68.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pliant Therapeutics Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pliant Therapeutics Inc's assets decreased by 22.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pliant Therapeutics Inc (2017–2024)
The table below shows the annual total assets of Pliant Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $396.95 Million | -22.49% |
| 2023-12-31 | $512.15 Million | +46.07% |
| 2022-12-31 | $350.61 Million | +58.49% |
| 2021-12-31 | $221.22 Million | -25.15% |
| 2020-12-31 | $295.53 Million | +148.21% |
| 2019-12-31 | $119.06 Million | +78.97% |
| 2018-12-31 | $66.53 Million | +915.24% |
| 2017-12-31 | $6.55 Million | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral,… Read more